2026/07/26 by Irina V. Wang, Courtney Davis, Robin Forrest +9
paper · doi:10.1002/cpt.70401
Information on new prescription drugs is increasingly complex and fragmented, posing challenges for healthcare professionals, patients, and payers. Clinicians require concise, actionable guidance to support prescribing decisions, while patients seek to balance benefits and harms when making decisions aligned with their treatment goals. Payers need comparative effectiveness data to inform coverage decisions that shape access and resource allocation. However, inadequacies in drug information communication often lead to overestimation of benefits and underestimation of harms. In this White Paper, we explore how information about newly approved drugs is generated, disseminated, and interpreted. We examine the information needs of healthcare professionals, patients, and payers and the influence of regulatory standards on available evidence. Focusing on regulated communication channels, such as prescription drug labeling, medication guides, and clinical trial snapshots, we highlight the foundational role of regulatory agencies in setting evidence standards and legitimizing drug information. We also consider alternative information sources, including pharmaceutical advertising, which coexist with regulated content. Against a backdrop of increasing uncertainty of drug approval evidence, we identify documented principles that regulators can adopt to meet drug information needs. Recommendations for improvements aim to better serve patients, support clinical decision making, and promote ethical healthcare resource allocation. While centered on the US context, the paper draws parallels with the European information landscape.